Jim Cramer on Catalyst Pharmaceuticals: “It’s a Very Inexpensive Stock”

“I similar Catalyst Pharmaceuticals. It really has, by the way, existent earnings, and it’s a precise inexpensive stock. I deliberation you’ve got a winner.”

A idiosyncratic with banal marketplace information connected a laptop. Photo by Anna Nekrashevich connected Pexels

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) provides treatments for patients managing uncommon conditions specified arsenic Lambert-Eaton myasthenic syndrome and Duchenne muscular dystrophy. During the occurrence that aired connected March 25, 2025, a caller inquired astir the banal and Cramer replied:

“No, I deliberation it’s precise bully and it’s had a precise bully year. It’s up much than astir each different drug, immoderate institution I follow. Yeah, we did similar it. Now retrieve this [is] inactive [a] tiny headdress banal and there’s immoderate insider selling, but I bash deliberation it’s conscionable a precise bully situation. We went implicit that a portion agone and it bushed the net estimates…. They were expected to gain 55 cents and earned 70 cents. That’s my benignant of stock. I deliberation you’re successful bully shape.”

It should beryllium noted that since the supra remark was aired, Catalyst Pharmaceuticals, Inc.’s (NASDAQ:CPRX) banal has declined by astir 13%.

While we admit the imaginable of CPRX arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the champion short-term AI stock.

READ NEXT: 30 Stocks That Should Double successful 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This nonfiction is primitively published astatine Insider Monkey.